Search results
Results from the WOW.Com Content Network
Bexagliflozin, sold under the brand name Bexacat, is an antidiabetic medication used to improve glycemic control in cats with diabetes. [2] Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor new animal drug approved by the US Food and Drug Administration (FDA) in any animal species. [2]
A tongue depressor or spatula is a tool used in medical practice to depress the tongue to allow for examination of the mouth and throat. Hobbyists , artists, teachers and confectionery makers use tongue depressors, which may also be referred to as craft sticks or popsicle sticks .
Canagliflozin is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for ...
The drugs were approved as additions to diet and exercise to improve blood sugar control in children aged 10 years and above with type 2 diabetes, the most common form of the disease. The ...
Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death. [ 2 ]
It is a disease with no cure or means of preventing it, and the only effective treatment is lifelong monitoring and insulin injections. FDA Approves First-of-Its-Kind Drug to Delay Type 1 Diabetes ...
A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday. The U.S. Food and Drug Administration approved Eli Lilly’s drug ...
The FDA approved the drug on January 29, 1997, and it appeared in pharmacies in late March. At the time, Dr. Solomon Sobel, a director at the FDA overseeing diabetes drugs, said in a New York Times interview that adverse effects of troglitazone appeared to be rare and relatively mild. [13]